2026 Interim report
Filed with HKEX · Stock code 9926 ·
6ix hasn’t read this filing yet.
View original source (HKEXnews)Company analysis
Earlier from Akeso
- Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
- Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
- Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
- Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026